Sangamo Therapeutics Inc (SGMO)

7.80
NASDAQ : Health Care
Prev Close 7.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.65 / 8.60
Avg Volume 1.25M
Exchange NASDAQ
Shares Outstanding 71.94M
Market Cap 586.30M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy

Collaboration combines Pfizer's heritage in Rare Disease, capabilities in gene therapy, and expertise in hemophilia with Sangamo's deep knowledge in genomic therapies

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Aratana Therapeutics, Trevena and Sangamo Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Sangamo Therapeutics Announces Special Regulatory Designations From The FDA For Three Clinical Programs

Rare Pediatric Disease Designation for SB-913 In Vivo Genome Editing Treatment for MPS II

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.

Sangamo Therapeutics Announces Presentation Of New Data Demonstrating Significant Reduction Of Tau Expression Using Proprietary ZFP Gene Regulation Technology

Engineered Zinc Finger Protein Transcription Factors Lowered Tau Levels by More Than 90% in Human Neurons In Vitro and Reduced Neuritic Dystrophy in Amyloid Mouse Model of Alzheimer's Disease

Commit To Purchase Sangamo Therapeutics At $3, Earn 20.4% Annualized Using Options

Investors eyeing a purchase of Sangamo Therapeutics Inc stock, but tentative about paying the going market price of $4.18/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 50 cents.

Sangamo Therapeutics Announces Chief Financial Officer Succession

Kathy Yi Appointed to Succeed H. Ward Wolff as CFO Upon His Retirement in March

Biotech Premarket Movers: BioCryst, Sangamo, Cempra

Biotech Premarket Movers: BioCryst, Sangamo, Cempra

BioCryst Pharmaceuticals, Sangamo Therapeutics and Cempra were among the biotech stock movers in premarket trading on Monday.

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Biotech Premarket Movers: IPXL, SGMO, ARLZ

Biotech Premarket Movers: IPXL, SGMO, ARLZ

Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.

Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering

Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering

- New architectures enable targeting of any chosen location in the genome with very high precision

Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies

Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies

Clear strategy with new management, organizational structure and clinical capabilities will drive Sangamo's industry-leading scientific platform into human studies

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A

SB-525 is one of four programs in the Company's newly focused clinical portfolio of in vivo genomic therapies for rare diseases

Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting

Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting

On Track to File Investigational New Drug Application for Hemophilia A Program by End of 2016

Sangamo BioSciences Makes Key Leadership Appointments To Strengthen Clinical And Commercial Capabilities

Sangamo BioSciences Makes Key Leadership Appointments To Strengthen Clinical And Commercial Capabilities

Dr. Edward Conner Appointed as Senior Vice President and Chief Medical Officer and Curt Herberts Promoted to Newly Created Role of Senior Vice President and Chief Business Officer